[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [ACTIVE] · [BUSINESS]

2 clusters · 3 sources · 26 days · First seen · Last updated

Silence Therapeutics financial and clinical developments

Overview

Silence Therapeutics, a biotechnology company specializing in RNA interference (RNAi) and siRNA therapies, has experienced significant financial and clinical developments.

In August 2026, the company upsized a public offering of approximately 12.9 million American Depositary Shares at $13.50 per share, aiming to raise roughly $175 million in gross proceeds. Following this announcement, the company’s share price rose from a previous close of $11.95 to an opening of $16.70.

By September 2026, the company’s stock had risen 111 percent since March. This surge was driven by successful interim results from a Phase II study of its drug candidate, Divesiran (SLN124), for the treatment of Polycythaemia vera. The study reported an 88 percent response rate, compared to a 19 percent response rate in the placebo group.

Entities

Silence Therapeutics · Ultragenyx Pharmaceutical · Cantor Fitzgerald · CommScope · William Blair

Timeline

  1. 7 days ago

    [BUSINESS] 3 sources
    Silence Therapeutics stock rises 111 percent on successful clinical trial results

    Silence Therapeutics stock has risen 111 percent following successful Phase II trial results for its blood disorder drug candidate, Divesiran, while Ultragenyx Pharmaceutical shares fell 46 percent.

  2. about 1 month ago

    [BUSINESS] 2 sources
    Silence Therapeutics prices upsized $175 million public offering

    Silence Therapeutics has priced an upsized $175 million public offering of ADSs, leading to a significant jump in its share price.

Sources

ad-hoc-news.de · DiePresse.com · sharedeals.de